Cargando…

Re: Remdesivir for the treatment of COVID-19 by Lee et al.

Detalles Bibliográficos
Autores principales:	Beccacece, Alessia, Ascoli Bartoli, Tommaso, Nicastri, Emanuele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531359/ https://www.ncbi.nlm.nih.gov/pubmed/36206865 http://dx.doi.org/10.1016/j.cmi.2022.09.015

Ejemplares similares

Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis
por: Tempestilli, Massimo, et al.
Publicado: (2021)

Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects
por: Tempestilli, Massimo, et al.
Publicado: (2022)

Monoclonal Antibodies for Pre- and Postexposure Prophylaxis of COVID-19: Review of the Literature
por: Vita, Serena, et al.
Publicado: (2022)

Correction to: Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis
por: Tempestilli, Massimo, et al.
Publicado: (2022)

Re: Lee H, et al. An Unusual Case of Myeloperoxidase-Positive Acute Megakaryoblastic Leukemia. Ann Lab Med 2015;35:466-8
por: Bennett, John M., et al.
Publicado: (2015)

Re: ‘Post-COVID-19 chronic symptoms’ by Davido et al.
por: Miglis, Mitchell G., et al.
Publicado: (2021)

Remdesivir and COVID-19
por: Ferrara, Francesco, et al.
Publicado: (2020)

Pulmonary administration of remdesivir in the treatment of COVID-19
por: Rasmussen, Henrik Berg, et al.
Publicado: (2020)

Remdesivir for the treatment of COVID-19: author's response
por: Lee, Todd C., et al.
Publicado: (2023)

Re: Efficacy of favipiravir in adults with mild COVID-19 by Bosaeed et al.
por: Mori, Nobuaki
Publicado: (2022)

Re: ‘ESCMID COVID-19 living guidelines: drug treatment and clinical management’ by Bartoletti et al
por: Dauby, Nicolas
Publicado: (2022)

Liver injury in remdesivir-treated COVID-19 patients
por: Zampino, Rosa, et al.
Publicado: (2020)

Reply to Lee et al.
por: Wang, Fei, et al.
Publicado: (2022)

Treatment of patients with COVID-19 on hemodialysis: Efficacy of remdesivir
por: Nakaya, Aya, et al.
Publicado: (2022)

Treatment of patients with COVID-19 on hemodialysis: Efficacy of remdesivir
por: Nakaya, Aya, et al.
Publicado: (2023)

Re: ‘Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients’ by Fiolet et al.
por: Lacout, Alexis, et al.
Publicado: (2021)

Re: ‘Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients’ by Fiolet et al.
por: Million, Matthieu, et al.
Publicado: (2021)

Re: Accelerating clinical trial implementation in the context of the COVID-19 pandemic by Diallo et al
por: Rys, Andrzej, et al.
Publicado: (2022)

Re: ‘the unique COVID-19 presentation of patients with B cell depletion’ by Belkin et al.
por: Múñez-Rubio, Elena, et al.
Publicado: (2023)

Comment on: Obesity is Associated with Improved Postoperative Overall Survival, Independent of Skeletal Muscle Mass in Lung Adenocarcinoma by Lee et al.
por: Lee, Duk‐Hee
Publicado: (2022)

Letter to the Editor re: Biglari et al. (2016)
por: Zura, Robert, et al.
Publicado: (2016)

Re: ‘Methodological evaluation of bias in observational COVID-19 studies on drug effectiveness’ by Wolkewitz et al.
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2021)

Does Remdesivir maintain the race in the general treatment protocol of COVID-19?
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2021)

Remdesivir for COVID-19: Why Not Dose Higher?
por: Yan, Victoria C., et al.
Publicado: (2021)

Re: 'Personal protective equipment protecting healthcare workers in the Chinese epicenter of COVID-19' by Zhao et al.
por: Wee, Liang En, et al.
Publicado: (2020)

Re: “High prevalence of heterotopic ossification in critically ill patients with severe COVID-19” by Stoira et al.
por: de l’Escalopier, Nicolas, et al.
Publicado: (2021)

Authors’ response: Re: Reifferscheid et al., “COVID-19 vaccine uptake and intention during pregnancy in Canada”
por: MacDonald, Shannon E., et al.
Publicado: (2022)

Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19)
por: Pallotto, Carlo, et al.
Publicado: (2021)

Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020)

Kaya et al. Is it a typical crosstalk: Need for re-implantation?
por: Akbarzadeh, Mohammad Ali
Publicado: (2015)

Drug Policies Skyline during COVID-19 Pandemic
por: Vita, Serena, et al.
Publicado: (2021)

Re: ‘Clinical course and outcomes of critically ill patients with COVID-19 infection: a systematic review’ by Serafim et al.
por: Lipes, Jed, et al.
Publicado: (2021)

Re: ‘Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis’ by Tleyjeh et al.
por: Koeckerling, David, et al.
Publicado: (2021)

Indian perspective of remdesivir: A promising COVID-19 drug
por: Singh, Devendra, et al.
Publicado: (2020)

Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?
por: Vitiello, Antonio, et al.
Publicado: (2021)

Remdesivir in moderate to severe COVID-19: A matter of time?
por: Bonazzetti, Cecilia, et al.
Publicado: (2021)

Remdesivir modifies interferon response in hospitalized COVID-19 patients
por: Murphy, Sarah L., et al.
Publicado: (2022)

Re: Hormonal therapies and venous thrombosis: The estrogen matters! Morimont et al.
por: LaVasseur, Corinne, et al.
Publicado: (2023)

Response to Krishnasamy et al
por: Morello, William, et al.
Publicado: (2022)

Remdesivir in Breastfeeding
por: Sadati, Elham, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ar4cvnenulp0i6q3ctgag5dnnk